Delayed encephalopathy after carbon monoxide (CO) poisoning (DEACMP) is still a clinical challenge. This study aimed to investigate the efficacy of combined therapy of mesenchymal stem cell (MSC) transplantation and butylphthalide in DEACMP patients.
Introduction
Carbon monoxide (CO) poisoning is not uncommon. Approximately 10% to 30% patients develop the delayed encephalopathy after carbon monoxide poisoning (DEACMP) despite successful treatment of the initial symptoms. After a period of pseudorecovery for around 1 month, these patients show acute symptoms of dementia and bladder/bowel dysfunction, and even disturbance of intelligence. [1, 2] The specific mechanisms of DEACMP are still unclear. Multiple factors have been found to be associated with the development of this condition, such as ischemia, hypoxia, cytotoxic injury, reperfusion injury, immune dysfunction, and neurotransmitter dysregulation. [3] CO can rapidly bind to hemoglobin, and then form carboxyhemoglobin. The binding ability of CO to hemoglobin is 300 times higher than that of oxygen, and the dissociation of CO from carboxyhemoglobin is 3600 times slower than that of oxygen. Thus the carboxyhemoglobin loses the ability of carrying oxygen, thereby leading to hypoxia. In addition, CO can also bind to the ferrous iron in the reduced cytochrome oxidase, which exaggerates the hypoxia. Although the carboxyhemoglobin concentration is lowered to the normal level, the residual intercellular CO continues to be a toxic factor by inhibiting the mitochondria, and finally causing the symptoms of DEACMP. The intermittent hypoxia after CO poisoning causes pathological changes in the brain similar to that of reperfusion. The reperfusion process produces large amounts of free radicals, which enhances the lipid oxidation of the cell membrane and causes mitochondrial dysfunction. In this process, the reperfusion process causes calcium ion overload, thereby leading to cell membrane hydrolysis by the membrane phospholipid, cellular organelle damage, and irreversible cell damage. Various therapies such as hyperbaric oxygen and free radical scavengers have failed in the management of DEACMP. [2, [4] [5] [6] Therefore, it is necessary to search for more effective treatments for DEACMP.
It is well-known that DEACMP is caused by cerebral dysfunction, and may be associated with central nervous system injury, [7, 8] which indicates that the recovery of central nervous system function may be a potential treatment for DEACMP. Notably, stem cell transplantation has been shown with great potential in repairing the nervous tissue by replacing the damaged cells. [9] Mesenchymal stem cells (MSCs) can be induced to differentiate into neurons or glial cells, which has been used to treat nervous system diseases. [10] However, few studies have reported the therapeutic potency of MSC transplantation on DEACMP. In addition, butylphthalide is a lipid-soluble drug with good blood-brain barrier permeability. [11] This novel drug has been approved for the treatment of cerebral ischemia in China. The treatment mechanisms of butylphthalide include mobilization of circulating endothelial progenitor cells [12] and promoting neurogenesis and neuroplasticity in the brain. [13] In addition, previous study has shown that butylphthalide has a neuroprotective effect in rats after acute CO poisoning. [14] We speculated that a combined therapy of MSC transplantation and butylphthalide might have a promising treatment outcome for DEACMP.
In this study, we prospectively treated 42 patients with either of 3 therapies: combined therapy of MSC transplantation and butylphthalide; MSC transplantation alone; or hyperbaric oxygen therapy. The efficacies and safety profiles of these treatments were examined.
Materials and methods

Patients
This prospective study was carried out from October 2012 to December 2015. Patients were included if they met the following criteria: had a history of CO exposure; had a period of pseudorecovery; with symptoms of dementia and bladder/bowel dysfunction, and even disturbance of intelligence and conscious; neuroimaging evidences. The exclusion criteria were as follows: history of severe allergy; shock; systemic infection or severe local infection; major organ dysfunction; coagulation disorders; positive of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or syphilis; genetic disorders. This study was approved by the Ethics Committee of our hospital. Informed consent was obtained from each patient.
MSC culture and characterization
A 8 to 10-cm long fresh umbilical cord was rinsed using normal saline. [15, 16] The cord lining, umbilical artery, and umbilical vein were dissected. The Wharton Jelly was obtained and cut into 1-mm 3 blocks. The Wharton Jelly blocks were washed using normal saline and then centrifuged at 2000 rpm for 5 minutes. After another washing and centrifugation, the supernatant was transferred to a culture flask, and 30-mL MSC culture medium (Biowit, BW110013, China) was added. The MSCs were incubated with 5% CO 2 at 37°C. The culture medium was replenished every 5 to 6 days. The cells were passaged every 10 days. As a result, the third passage of the cells was used for transplantation.
For MSC characterization, the third passage of the cells were digested using 0.25% trypsin and then incubated with the following antibodies: rabbit-anti human CD106-PE, CD45-PE, CD34-PE, CD29-FITC, CD44-FITC, CD-14-PE, CD31-PE, HL-DR-FITC (BD Biosciences) at room temperature for 30 minutes. The cells were examined using a flow cytometer (Beckman).
Treatment protocol
The patients were randomized into 3 groups. The combinedtherapy group (n = 14) received both MSC transplantation and butylphthalide, the MSC group (n = 15) received MSC transplantation alone, and the control group (n = 13) was managed with hyperbaric oxygen therapy and symptomatic treatments.
The MSCs were alternatively injected into the subarachnoid space and the carotid artery using a self-made high-pressure injector. The interval between each injection was 5 to 7 days. A total of 1 to 2 Â 10 7 MSCs were injected each time. A therapy cycle included 4 injections. A second cycle was used if the first cycle did not achieve adequate efficacy. In the combined-therapy group, 100 mL butylphthalide was intravenously infused twice every day. A cycle of butylphthalide treatment was 14 days.
Outcome evaluation
All patients were evaluated using the Mini-Mental State Examination (MMSE) [17] and the Barthel index of activities of daily living [18] before the treatment and at 1 month, 3 months, and 6 months after the treatment. Computed tomography (CT) and magnetic resonance imaging (MRI) results before and after the treatment were compared.
Statistical analysis
Continuous data are presented as mean ± standard deviation (SD). Categorical data are presented as percentages. Comparisons were made using the analysis of variance (ANOVA) test or the chi-square test. All statistical analyses were performed using the SPSS 16.0 software (SPSS, Chicago, IL). A P value less than 0.05 was considered statistically significant.
Results
Basic patient information
The basic patient information is shown in Table 1 . No significant difference was found in basic information among the combined therapy, MSC, and control groups. All patients showed acute neurologic symptoms of dementia, bladder/bowel dysfunction, and disturbance of intelligence and conscious after the pseudorecovery period. 
MSC characterization
Over 90% of the MSCs were positive for CD44, CD73, and CD90. The MSCs were negative for CD34 and CD45.
Neuroimages
The CT images were obtained from 25 patients. The results showed that 6, 6, and 7 cases of abnormal CT, including mild, intermediate, and severe changes, respectively, were found in the combined therapy, MSC, and control groups before treatment ( Table 2 ). Mild changes in the CT images were defined as unilateral or bilateral low-density lesions in the basal ganglia, and the globus pallidus was primarily involved. Intermediate to severe changes in the CT images were considered as broad low-density lesions in the subcortex white matter, and symmetrical or unsymmetrical low-density patches with unclear borders in the frontal white matter, globus pallidus, lentiform nucleus, and genu of internal capsule. MRI images were obtained from 17 patients. Before treatment, abnormal MR, including mild, intermediate, and severe changes, were observed in 8 cases of combinedtherapy group, 9 cases of MSC group, and 6 cases of control group (Table 2) . Mild changes in the MRI images were long T1 and long T2 oval abnormal signals in the bilateral globus pallidus. Intermediate to severe changes in the CT images were defined as lesions in the periventricular matter, and lesions symmetrical to the centrum ovale. The lesions were T2-weighted hyperintense and T1-weighted hypointense, with signs of chronic ischemia in the basal ganglia or the globuspallidus. After treatment, we found that only 1 case of abnormal MR and CT was found in combined-therapy group, whereas 6 and 8 cases of abnormal MR and CT were, respectively, observed in the MSC group and the control group ( Table 2) . As a result, radiological response rate in combined-therapy group (92.9%, 13/14) was significantly higher than that in the MSC (60.0%, 9/15) and control groups (38.5%, 5/13). There were significant differences in the radiological response rate among the 3 groups (P < 0.05; Table 2 ).
Treatment efficacy
At 1 month, 3 months, and 6 months after the treatment, the MMSE scores (Table 3) were all significantly higher in the combined-therapy group than those in the MSC and control groups, respectively (7. 
Safety profile
In the combined-therapy group, a few patients ran a low fever. No other complications were seen in our patients such as puncture site bleeding or infection.
Discussion
Our study showed that the combined therapy of MSC transplantation and butylphthalide significantly improved the Table 2 Radiological responses after the treatment.
Combined-therapy group (n = 14) MSC group (n = 15) Control group (n = 13) P CT = computed tomography, MR = magnetic resonance, MSC = mesenchymal stem cell. Table 3 The MMSE scores of the 3 groups.
Combined-therapy group (n = 14) MSC group (n = 15) Control group (n = 13) P Table 4 The Barthl scores of the 3 groups.
Combined-therapy group (n = 14) MSC group (n = 15) Control group (n = 13) P [10] The underlying mechanism was that the MSCs located and surrounded the diseased tissue, then formed a network to repair the damaged neural tissue, enabling the recovery of the lost neural functions. [19] In the microenvironment of the central nervous system, MSCs could promote the repair of the injured tissue and decreasing cell necrosis by secreting brainderived neurotrophic factor and basic fibroblast growth factor, or stimulating the injured brain area to produce endogenous factors. Previous study revealed that the MSCs were transplanted into the brain and differentiated into neuron-like cells or astrocytes, and then the MSC-derived cells survived around the injured brain area and even migrated to the whole brain. [20] MSCs could differentiate into vascular endothelial cells, thereby protecting the neurons and promoting angiogenesis. [21] MSCs could secret multiple neurotrophic factors and active the endogenous neural stem cells, and also differentiate into neural cells to replace the damaged cells, which was the endogenous route of neural repair.
Several theories had been proposed to explain the mechanisms of stem cells passing through the blood-brain barrier. [22] [23] [24] Adhesion molecules might mediate the migration of MSCs. Brain damage could cause a series of inflammatory reactions in the brain, and then the inflammatory mediators induced the endothelial cells to express intercellular adhesion molecules and vascular cell adhesion molecules. The weak point of the blood-brain barrier might be involved in the migration of MSCs. It had been reported that a special transport means might exist. The local microvascular system expressed a certain adhesion molecule, which adhered to the MSCs and mediated its migration through the blood-brain barrier. [25] Most present treatment methods for DEACMP were designed to target the damaged but sill survived brain cells by providing neurotrophic and functional supports. In DEACMP, necrosis and apoptosis occurred in large amounts of neurons, and demyelination was severe. It was impossible to recover the lost neural functions and mitigate the symptoms merely by reviving the survived neural cells. In our study, MSCs were alternatively injected into the subarachnoid space and the carotid artery to increase the contact volume and contact chance of the MSCs with the injured brain tissue. A self-made high-pressure injector was used to inject the MSCs directly into the carotid artery. In addition, butylphthalide induced the MSCs in vivo into new neurons and glial cells, replacing the dead brain cells and forming new myelin sheath. Butylphthalide was lipid-soluble and could pass the blood-brain barrier, which might help the MSCs pass the blood-brain barrier. The nerve tracts were re-established and the neural functions were repaired. Thus, the neurologic and psychiatric symptoms of DEACMP were improved.
Limitations
Undoubtedly, our study has several limitations. The first limitation is the small sample of this study; more prospective studies with larger sample size should be carried out to confirm the results of this study. Second, longer longitudinal follow-up is required to confirm the treatment effect of combined therapy of butylphthalide and MSC transplantation in DEACMP.
Conclusions
In conclusion, the combined therapy of butylphthalide and MSC transplantation might be safe and effective in treating DEACMP. This treatment method showed superior efficacy in comparison with MSC transplantation alone and hyperbaric oxygen therapy.
